SRT3

229

+0.66%↑

BIM

116.6

+0.95%↑

ORNBV.FI

54.85

+0.37%↑

GXI

60.6

+0.5%↑

ICAD

21.46

+0.47%↑

SRT3

229

+0.66%↑

BIM

116.6

+0.95%↑

ORNBV.FI

54.85

+0.37%↑

GXI

60.6

+0.5%↑

ICAD

21.46

+0.47%↑

SRT3

229

+0.66%↑

BIM

116.6

+0.95%↑

ORNBV.FI

54.85

+0.37%↑

GXI

60.6

+0.5%↑

ICAD

21.46

+0.47%↑

SRT3

229

+0.66%↑

BIM

116.6

+0.95%↑

ORNBV.FI

54.85

+0.37%↑

GXI

60.6

+0.5%↑

ICAD

21.46

+0.47%↑

SRT3

229

+0.66%↑

BIM

116.6

+0.95%↑

ORNBV.FI

54.85

+0.37%↑

GXI

60.6

+0.5%↑

ICAD

21.46

+0.47%↑

Search

Sanofi SA

Chiusa

SettoreSettore sanitario

92.74 1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

91.82

Massimo

93.31

Metriche Chiave

By Trading Economics

Entrata

1.4B

1.9B

Vendite

3B

11B

P/E

Media del settore

19.239

54.379

EPS

1.79

Rendimento da dividendi

4

Margine di Profitto

17.65

Dipendenti

82,878

EBITDA

2.2B

2.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+25.41% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

4.00%

2.55%

Utili prossimi

31 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-13B

117B

Apertura precedente

91.74

Chiusura precedente

92.74

Notizie sul Sentiment di mercato

By Acuity

37%

63%

144 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Sanofi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2025, 11:29 UTC

Acquisizioni, Fusioni, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- 2nd Update

5 mag 2025, 09:09 UTC

Acquisizioni, Fusioni, Takeovers

Santander to Sell Poland Assets to Austria's Erste Group for $7.9 Billion -- Update

5 mag 2025, 07:25 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Buy Santander Assets in Poland for $7.91 Billion

30 apr 2025, 05:23 UTC

Utili

Santander Confirms Outlook After Quarterly Beat

8 mag 2025, 17:55 UTC

Utili

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

8 mag 2025, 15:12 UTC

Utili

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

6 mag 2025, 06:16 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Santander's Polish Business Disposal Is Attractive -- Market Talk

6 mag 2025, 06:13 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Erste's Cash Deal for Santander Bank Polksa Seen as Positive -- Market Talk

5 mag 2025, 14:11 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Erste Group Adds Exposure to Fast-Growing Polish Market, But Could Face Risk -- Market Talk

5 mag 2025, 11:30 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Sale of Polish Business Strengthens Santander's Capital Position -- Market Talk

5 mag 2025, 06:48 UTC

Acquisizioni, Fusioni, Takeovers

Santander Intends to Take Full Ownership of Santander Consumer Bank Polska

5 mag 2025, 06:48 UTC

Acquisizioni, Fusioni, Takeovers

Santander Will Own 13% of Santander Polska Following Transaction

5 mag 2025, 06:47 UTC

Acquisizioni, Fusioni, Takeovers

Santander, Erste Enter Cooperation in Corporate & Investment Banking, Payments

5 mag 2025, 06:46 UTC

Acquisizioni, Fusioni, Takeovers

Santander Expects EUR2B Net Capital Gain From Deal

5 mag 2025, 06:46 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Says Profitability Is Set to Improve Significantly After Deal

5 mag 2025, 06:45 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Targets Return to Current Dividend Payout Range of 40-50% From 2026

5 mag 2025, 06:45 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Reduce 2025 Dividend Payout to Maximum of 10% of Net Profit

5 mag 2025, 06:45 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group: Dividend for 2024 Remains Unchanged at EUR3 a Share

5 mag 2025, 06:44 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Temporarily Reduce Dividend Payout

5 mag 2025, 06:43 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Cancel Planned EUR700M Buyback

5 mag 2025, 06:42 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Will Fund the Acquisition Exclusively From Internal Resources

5 mag 2025, 06:40 UTC

Acquisizioni, Fusioni, Takeovers

Santander Says It Plans to Distribute EUR3.2B Through Buybacks

5 mag 2025, 06:39 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Buy 49% of Santander Polska's for PLN584 a Share

5 mag 2025, 06:38 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Buy 49% Stake in Poland Unit of Banco Santander

5 mag 2025, 06:37 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group to Become No. 3 Bank in Poland Through Deal

5 mag 2025, 06:36 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Also Acquires 50% in Asset Management Firm Santander TFI for EUR200M

5 mag 2025, 06:35 UTC

Acquisizioni, Fusioni, Takeovers

Erste Group Buying 49% Stake in Santander Bank Polska for EUR6.8B

30 apr 2025, 09:00 UTC

Notizie principali
Utili

Santander Beats Estimates on Spain, U.S. Strength -- Update

30 apr 2025, 07:57 UTC

Discorsi di Mercato
Utili

Santander's U.K., Brazil Prints Disappoint -- Market Talk

30 apr 2025, 06:02 UTC

Discorsi di Mercato
Utili

Santander's Underlying Trends Meet Expectations -- Market Talk

Confronto tra pari

Modifica del prezzo

Sanofi SA Previsione

Obiettivo di Prezzo

By TipRanks

25.41% in crescita

Previsioni per 12 mesi

Media 115.073 EUR  25.41%

Alto 127 EUR

Basso 95 EUR

Basato su 15 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

15 ratings

11

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

91.3 / 96.1Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

144 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.